Health-related quality of life in patients with pulmonary arterial hypertension
Health-related quality of life in patients with pulmonary arterial hypertension
复制标题
DOI：
10.1186/1465-9921-6-92
复制
发表时间：
2005-08-10
影响因子：
5.8
通讯作者：
Palevsky, H
中科院分区：
文献类型：
--
作者：
Taichman, DB;Shin, J;Palevsky, H
工作背景：随着肺动脉高压患者治疗选择的扩大，结局的改善为在接近治疗时考虑其他终点提供了机会，包括影响健康相关生活质量的因素。然而，相对知之甚少的是健康相关的生活质量及其决定因素的患者肺动脉高压。方法：健康相关的生活质量进行了评估，在一项横断面研究的155名门诊肺动脉高压患者使用通用和泌尿系统疾病的具体测量工具。大多数患者有世界卫生组织功能II级或III级症状。人口统计学，血流动力学和治疗变量进行了评估与健康相关的生活质量scores.Results：肺动脉高压患者遭受严重损害的身体和情感领域的健康相关的生活质量。特发性（原发性）肺动脉高压患者的健康相关生活质量最好，而系统性硬化症患者的健康相关生活质量最差。更长的6分钟步行距离与更好的健康相关生活质量评分相关，功能性II级与III级症状也是如此。然而，血流动力学测量与健康相关的生活质量评分无关。健康相关的生活质量之间没有差异，发现正在接受钙通道拮抗剂，波生坦或持续输注前列环素治疗的患者在生活质量assessment.Conclusion：健康相关的生活质量严重受损的肺动脉高压患者，并与功能状态的措施。与健康相关的生活质量受损的具体关联表明有针对性的干预的潜在领域。
Background: Improved outcomes with expanding treatment options for patients with pulmonary arterial hypertension present the opportunity to consider additional end-points in approaching therapy, including factors that influence health-related quality of life. However, comparatively little is known about health-related quality of life and its determinants in patients with pulmonary arterial hypertension.Methods: Health-related quality of life was evaluated in a cross sectional study of 155 outpatients with pulmonary arterial hypertension using generic and respiratory-disease specific measurement tools. Most patients had either World Health Organization functional Class II or III symptoms. Demographic, hemodynamic and treatment variables were assessed for association with health-related quality of life scores.Results: Patients with pulmonary arterial hypertension suffered severe impairments in both physical and emotional domains of health-related quality of life. Patients with idiopathic ("primary") pulmonary arterial hypertension had the best, and those with systemic sclerosis the worst health-related quality of life. Greater six-minute walk distance correlated with better health-related quality of life scores, as did functional Class II versus Class III symptoms. Hemodynamic measurements, however, did not correlate with health-related quality of life scores. No differences in health-related quality of life were found between patients who were being treated with calcium channel antagonists, bosentan or continuously infused epoprostenol at the time of quality of life assessment.Conclusion: Health-related quality of life is severely impaired in patients with pulmonary arterial hypertension and is associated with measures of functional status. Specific associations with impaired health-related quality of life suggest potential areas for targeted intervention.